New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders

doi:10.4239/wjd.v6.i15.1285

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (25065)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

756

WORD

381

HTML

17240

Figures (1-1)

537

Tables (1-1)

523

Sum=19437

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

627

Download

1661

Sum=2288

Publishing Process of This Article

Item

Count

Browse

1261

Download

2079

Sum=3340

Nov 10, 2015 (publication date) through Oct 26, 2025

Times Cited of This Article

Times Cited (51)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Diabetes. Nov 10, 2015; 6(15): 1285-1295
Published online Nov 10, 2015. doi: 10.4239/wjd.v6.i15.1285

Table 1 Incretin-based drugs currently approved by the European Medicines Agency

Drug name	Primary mechanism of action	EMA approval date
Exenatide	GLP-1 receptor agonist	Nov-06
Sitagliptin	DPP-4 inhibitor	Mar-07
Vildagliptin	DPP-4 inhibitor	Sep-07
Liraglutide	GLP-1 receptor agonist	Jun-09
Saxagliptin	DPP-4 inhibitor	Oct-09
Exenatide-LAR	GLP-1 receptor agonist	Jun-11
Linagliptin	DPP-4 inhibitor	Aug-11
Lixisenatide	GLP-1 receptor agonist	Feb-13
Alogliptin	DPP-4 inhibitor	Sep-13
Dulaglutide	GLP-1 receptor agonist	Jan-15

DPP-4: Dipeptidyl peptidase 4; GLP-1: Glucagon-like peptide-1; LAR: Long-acting release; EMA: European medicines agency.

Full Size Table

Citation: Irwin N, Flatt PR. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. World J Diabetes 2015; 6(15): 1285-1295
URL: https://www.wjgnet.com/1948-9358/full/v6/i15/1285.htm
DOI: https://dx.doi.org/10.4239/wjd.v6.i15.1285